- Home
- MLYS vs PHAR Comparison
MLYS vs PHAR Comparison
Compare MLYS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- PHAR
- Stock Information
- Founded
- MLYS 2019
- PHAR 1988
- Country
- MLYS United States
- PHAR Netherlands
- Employees
- MLYS N/A
- PHAR N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- PHAR Health Care
- Exchange
- MLYS Nasdaq
- PHAR Nasdaq
- Market Cap
- MLYS 1.0B
- PHAR 718.1M
- IPO Year
- MLYS 2023
- PHAR N/A
- Fundamental
- Price
- MLYS $14.54
- PHAR $10.27
- Analyst Decision
- MLYS Strong Buy
- PHAR Strong Buy
- Analyst Count
- MLYS 4
- PHAR 3
- Target Price
- MLYS $27.00
- PHAR $30.00
- AVG Volume (30 Days)
- MLYS 862.9K
- PHAR 4.3K
- Earning Date
- MLYS 08-12-2025
- PHAR 07-31-2025
- Dividend Yield
- MLYS N/A
- PHAR N/A
- EPS Growth
- MLYS N/A
- PHAR N/A
- EPS
- MLYS N/A
- PHAR N/A
- Revenue
- MLYS N/A
- PHAR $320,708,000.00
- Revenue This Year
- MLYS N/A
- PHAR $13.31
- Revenue Next Year
- MLYS N/A
- PHAR $7.68
- P/E Ratio
- MLYS N/A
- PHAR N/A
- Revenue Growth
- MLYS N/A
- PHAR 24.13
- 52 Week Low
- MLYS $8.24
- PHAR $6.65
- 52 Week High
- MLYS $18.38
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- MLYS 47.97
- PHAR 49.06
- Support Level
- MLYS $13.22
- PHAR $10.46
- Resistance Level
- MLYS $14.54
- PHAR $11.49
- Average True Range (ATR)
- MLYS 0.71
- PHAR 0.34
- MACD
- MLYS 0.00
- PHAR -0.12
- Stochastic Oscillator
- MLYS 68.37
- PHAR 31.46
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.